FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 774 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Getting Help for Sexual Health Problems When You Have Head and... April 14, 2022 Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... January 17, 2023 Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival... March 22, 2022 Load more HOT NEWS Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable... Rescued From Complete Darkness Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated...
